CorMedix (CRMD) Stock: Here’s Why It’s Running For The Top!

2

CorMedix Inc. (NYSEAMERICAN: CRMD) is making its way for the top this morning. However, many are scratching their heads wondering why. There haven’t been any press releases or SEC filings issued by the company.

Nonetheless, there is a very good reason for the gains. Today, we’ll talk about:

  • Why CRMD stock is headed up;
  • what we’re seeing from the stock; and
  • what we’ll be watching for ahead.

Here’s Why CRMD Stock Is Climbing

As mentioned above, CorMedix is having a strong start day in the market today, but no news has been released. So, what’s the deal?

While there has been nothing from the company’s investor relations team, there is an upcoming event that is proving to be the source of the excitement. According to the Roth Conference Calendar, CRMD will be presenting at one of the largest investing conferences in the world.

The calendar has the company as a presenter on Monday, March 18, 2019 at 2:00 p.m.

While it is unusual for a company not to announce that it will be presenting at such a large conference, the calendar confirms that the appearance will be taking place. However, with no news from the company, we can only speculate as to the topic of the presentation.

Nonetheless, if I were to guess, I would expect that CRMD would provide an update with regard to the development of Neutrolin, recent data and conversations with the FDA seem to be positive. So, I would imagine that the company would want to ride this wave.

This is very good news for the company and its investors. After all, not only will the company be presenting, attendance at the conference will allow the company to mingle with market leaders, potential partners, and potential big-money investors. All in all, the conference could open doors for the company.

What We’re Seeing From The Stock 

While CorMedix hasn’t issued any news as of yet, investors seem to be finding the Roth calendar and taking note that the company will be presenting. This is leading to excitement and sending the stock screaming for the top.

As is just about always the case, our partners at Trade Idaes were the first to alert us to the gains. Currently (11:47), CRMD is trading at $1.72 per share after a gain of $0.09 per share or 5.50% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CRMD. In particular, we’re interested in following the company’s continued work to bring its Neutrolin product to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

What Do You Think?

Where do you think CRMD is headed? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


2 COMMENTS

  1. Good article on CRMD! Please continue to follow and post articles. It is an exciting stock with a lot of followers and potential as FDA NDA filing could be just weeks away!

LEAVE A REPLY

Please enter your comment!
Please enter your name here